CVS Health Corporation Q4 FY2025 earnings call

• Aetna business: Dramatically improved financial results with over $2.6B YOY adjusted operating income improvement, refreshed leadership, improved culture, received Press Ganey Health Plan of the Year award, and advocates for appropriate funding for Medicare Advantage.
• Pharmacy businesses: Caremark focuses on driving savings, adapts to regulatory changes; CVS Pharmacy exceeded expectations in 2025, transitioned to cost-based reimbursement.
• 2025 performance: Delivered adjusted EPS of $6.75, operating cash flow of $10.6B; Aetna's Medicare business made progress; pharmacy businesses had a turnaround.
• 2026 outlook: Reaffirms 2026 adjusted EPS guidance range of $7 to $7.20 and revenue at least $400B; focuses on simplifying healthcare, improving connectivity between businesses.

In Health Care Benefits, the quarter generated over $36 billion in revenue, a 10%+ increase from prior year, driven by the Government business due to IRA impact on Medicare Part D. It had an adjusted operating loss of $676 million. The Health Services segment had revenues over $51 billion, a 9% YOY increase, with adjusted operating income of approximately $1.9 billion, a 9%+ YOY increase. The Pharmacy & Consumer Wellness segment had revenues nearly $38 billion, a 12%+ YOY increase, with adjusted operating income over $1.9 billion, a nearly 9% YOY increase.

• Reaffirms full year 2026 adjusted EPS guidance range of $7 to $7.20 and revenue at least $400B.
• Updates 2026 cash flow from operations to at least $9B.
• Expect 2026 to be another strong year with progress towards target margins, including margin improvement in Medicare driven by pricing discipline, cautious outlook on Medicaid due to industry pressures, and strong performance in Commercial due to pricing discipline.

• Medicare Advantage advanced rate notice not matching medical cost trend, impacting Aetna's margins.
• FTC proposals and PBM legislation may hinder supply chain negotiation and affect PBM margins.
• Elevated medical cost trends pose challenges to maintaining margins across segments.

Q: Justin Lake asked about Medicare Advantage rates and impact on trajectory.

A: David Joyner and Steven Nelson discussed, noting the advanced rate notice is disappointing but commitment to Aetna margins remains unchanged and it doesn't impact long-term enterprise guide.

Q: Lisa Gill inquired about FTC proposals, PBM legislation, and long-term margins.

A: David Joyner and Ed DeVaney responded, stating PBM value remains intact, legislation aligns with past changes, and margin profile will be durable.

Q: Michael Cherny asked about PCW market positioning.

A: Len Shankman and David Joyner answered, highlighting PCW's progress, investments in consumer experience, and local assortment strategies.

Q: Andrew Mok questioned medical membership and commercial rebates.

A: Steven Nelson responded, noting strong commercial membership growth due to better retention and innovative products.

Q: Elizabeth Anderson asked about Medicaid rates and MLR.

A: Steven Nelson answered, stating Medicaid business performing in line with expectations with cautious outlook on performance.

Q: George Hill asked about MLR directional pieces.

A: Brian Newman and Steven Nelson responded, discussing margin improvement in Medicare, cautious outlook on Medicaid, and strong performance in Commercial.

Q: Erin Wright asked about technology investments.

A: Brian Newman and Prem Shah answered, discussing AI utilization across enterprise and progress on open engagement platform.

Q: Ann Hynes asked about health insurance margins and trends.

A: Brian Newman and Steven Nelson responded, discussing margin improvement in Medicare, stable margins in Medicaid, and strong performance in Commercial.